Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan
Ming Zhao(First Affiliated Hospital of Sichuan Medical University), Funda Meric‐Bernstam(The University of Texas MD Anderson Cancer Center)
Cited by 27
Related Papers
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial
|Journal of Clinical Oncology|2023|882
Oxidative Phosphorylation Is a Metabolic Vulnerability in Chemotherapy-Resistant Triple-Negative Breast Cancer
|Cancer Research|2021|155
Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors
|Endocrine Related Cancer|2008|148
Vertical inhibition of the PI3K/Akt/mTOR pathway is synergistic in breast cancer
|Oncogenesis|2017|72